Larimar Therapeutics, Inc. (LRMR) announced promising preliminary results on Monday from the long-term open-label extension (OLE) study of nomlabofusp, a treatment being tested in individuals with Friedreich's Ataxia.
Friedreich's Ataxia is an inherited disorder characterized by progressive degeneration of the nervous system. The OLE study results indicated that nomlabofusp treatment led to an increase in frataxin levels among participants. Given that a deficiency in frataxin is the underlying cause of Friedreich's Ataxia, boosting these levels could potentially decelerate the disease's progression.
The company reiterated its schedule to launch a registrational study for nomlabofusp by mid-2025 and plans to file a Biologics License Application (BLA) in the latter half of 2025.
